Navigation Links
The Quigley Corporation Reports First Quarter 2009 Results
Date:5/1/2009

stage of data collection, evaluation and study conclusions. The Company, after collecting all the patient information from 21 Study centers and conferring with its panel of experts on the data, will draft and report study conclusions

The Phase IIb study was designed to evaluate the safety and efficacy of QR-333, a unique topical formulation designed to offer physicians and patients an effective, easy to administer, safe treatment for Diabetic Peripheral Neuropathy with little to no side effects. To date there is no fully effective treatment for diabetic neuropathy. Current treatment options are limited to products such as NSAIDs, analgesics, anticonvulsants, antidepressants, etc., which are often not well tolerated by patients.

As announced by the Company on April 30, 2009, the Diabetic Peripheral Neuropathy Phase IIb clinical study demonstrated a significant improvement in two key measures of distal sensory nerve function in the group treated with QR-333. The compound was applied topically to the feet of subjects suffering from painful diabetic neuropathy and over the course of 12 weeks, significantly improved both maximal conduction velocity and compound sensory amplitude in the sural nerve. The mean improvement in nerve conduction velocity exceeded the change considered by thought leaders to be "clinically meaningful" in clinical studies. The sural nerve carries sensation from the feet and its pathology is the fundamental cause of foot pain and ultimately foot ulcers and amputation in some diabetic subjects.

These findings necessitate a change in the potential outlook for this investigational new drug. The Diabetic Peripheral Neuropathy market has significant unmet need for rational, mechanism-based drugs. These clinically significant findings suggest disease modification in this (12 week) phase II b study. The Company is aware that this is a finding in a subset of the patient population. Since the obse
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
2. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
3. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
4. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
5. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
6. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
7. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
8. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
9. Providence Service Corporation to Report First Quarter 2009 Results on Wednesday, May 6th After the Market Closes
10. Protein Sciences Corporation Appoints New Board of Directors
11. Digirad Corporation Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... This report provides quantitative analysis ... The analysis includes market size data by revenue ... company share data by revenue in 2013 for ... It uses data and information sourced from proprietary ... , Scope,     Information on market ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 BCC ... report, SYNTHETIC BIOLOGY: GLOBAL MARKETS , the ... to nearly $11.9 billion in 2018, with a ... Enabled products account for the fastest growing segment, ... CAGR. Synthetic biology-enabled products in the pharmaceutical/diagnostics, chemical, ...
(Date:7/14/2014)... July 14, 2014 Secure Decisions, a ... is partnering with the Software Assurance Marketplace (SWAMP) to ... the software that drives everyday life. , The SWAMP, ... housed in the Morgridge Institute for Research, is funded ... advance software security practices by building a free facility ...
(Date:7/14/2014)... Clearwater, Florida (PRWEB) July 14, 2014 ... Summer Open House event will be held at the ... Wednesday July 16th from 4-8pm. Wine and other refreshments ... advantage of retail discounts on beauty products ... skin treatment known as dermaplaning. , Dermaplaning (also ...
(Date:7/14/2014)... July 14, 2014 The Encino ... now offering Lumineers and porcelain veneers. These ... that require more preparation and greater loss of healthy ... shells to conceal visible flaws on the tooth. Encino ... closely with patients to ensure they offer the most ...
Breaking Medicine News(10 mins):Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2
... finds cavities before X-rays allowing, dentists to ... TORONTO, July 3 /PRNewswire/ - Quantum Dental ... technology which,detects and monitors the early onset of ... reduces the number of invasive and painful procedures,and ...
... G8 failure on food prices, biofuels, and climate ... world,s population - at risk of hunger, warns,anti-poverty ... ahead of the G8,summit in Hokkaido, Japan, ActionAid ... has Contributed to the Global Food Crisis and ...
... completely fabricated,item about GO3 Omega-3 fish oil capsules ... Star magazine, none of the parties named in ... magazine prior to publication., (Photo: http://www.newscom.com/cgi-bin/prnh/20080702/LAW528 ... and will vigorously pursue any,organization making false claims ...
... Roger Mason Jr,Washington Wizards Guard and Washington, ... a Cause on July 29 featuring bowling at ... coming out to support the,cause, including Brendan Haywood ... Anthony, Allen Iverson, Vince Carter, Kevin Durant, and,Chris ...
... Technology could one day help tailor treatments to individual patients, ... new technique for finding and analyzing stray cancer cells in ... for doctors to one day not only determine the genetic ... cells and adjust treatments accordingly. , "I think this ...
... John Albright, MD, will join three other physicians as a 2008 ... , ... Orlando, Florida (PRWEB) July 2, 2008 -- ... three other physicians as a 2008 American Orthopaedic Society for ...
Cached Medicine News:Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 2Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 3Health News:ActionAid Challenges G8 on Response to Food Crisis 2Health News:GO3 Statement Regarding Erroneous Coverage in Star Magazine 2Health News:Washington Wizards Guard Roger Mason Jr. to Host Bowling at Lucky Strike to Benefit National Kidney Foundation of the National Capital Area 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 3Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3
(Date:7/14/2014)... , July 14, 2014 Lumin Medical ... the assets of PatientTrak, the leading provider of on-demand ... from Illinois to ... is Lumin which means light and our mission is ... patient satisfaction, increase efficiencies and reduce costs," said ...
(Date:7/14/2014)... N.J. , July 14, 2014  Invivotek ... LLC is pleased to announce that its animal ... Association for the Assessment and Accreditation of Laboratory ... treatment of animals in science worldwide through voluntary ... standards for animal care and use in 38 ...
(Date:7/14/2014)... 14, 2014  Remedy Informatics, the leading provider ... and life sciences research, announced that it has ... to build the first-ever national patient registry devoted ... pancreatitis. "The National Pancreas Foundation is ... thoughtful and committed organizations can effect upon society ...
Breaking Medicine Technology:Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3
... 4, 2012  Elevation Pharmaceuticals, Inc. announced today the closing ... investor Novo Ventures , to fund development of Elevation,s ... disease (COPD). All previous investors participated in the round, including ... Capital and Mesa Verde Venture Partners . In ...
... 4, 2012 /PRNewswire-iReach/ -- DFH Pharma, ... focused exclusively in the HIV-1 therapeutic space, announced ... medicinal chemistry services to support DFH efforts to ... drugs. Maturation inhibitors are a novel class of ...
Cached Medicine Technology:Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy 2Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy 3DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 3
Round knurled handle. Overall length 130 mm....
Optimum Extra Strength cleaner is a sterile non-preserved cleaning solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and all hard contact lenses of any pol...
Round knurled handle. Overall length 130 mm....
Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
Medicine Products: